medic suppli devic
reason report
bottom line publish individu one-pag compani
preview ortho
compani preview follow page high level expect
compani across univers mostli deliv posit organ
could limit degre organ upsid surpris actual flow
compani bottom line -- -especi large-cap
think cc revenue guidanc rang like creep higher suspect fx
could limit potenti upward ep rang reiter like
top pick year large-cap mid-
cap small-cap pick spot quarter
base believ core fundament healthi
growth acceler organ revenue upsid confid
valid improv core fundament
 expect lower intra-qtr market-rel non-
creat better set-up rev/ep
growth acceler attract investor look posit next year
op top large-cap revenue growth acceler
look set start take form multipl signific
discount current continu move higher
clear path revenue growth acceler margin improv
higher ep growth move past
suppli issu new product launch unfold rosa
compani inform svb leerink llc research
pleas refer page analyst certif import disclosur price chart disclosur specif
cover compani statement valuat risk avail
recent month rais bar rel weve
accustom head print
believ deliv ex-fx revenue out-performance
importantli sell day adj revenue growth acceler
op top mid-cap pick given acceler revenue
growth trajectori leverag ep growth acceler
prospect view stock recent
set-up fx transient continu
believ enough levers/driv year
period sustain hsd revenu growth
deliv mid-teen ep growth least -- -a better profil
mani peer think investor look past
minor increment fx-driven margin pressur
long cc revenue growth beat expect think
real possibl vs consensu management
reiter ep outlook despit increment fx
headwind think investor continu gravit
stori given durabl multi-year revenue growth
driver manta ezplaz urolift urolift
japan think investor continu get excit
help support premium valuat
op continu believ current
valuat ev/sal discount group
disloc compani growth
prospect acceler potenti
intra-quart check suggest overal us
wake neg media attent
accompani may fda breast implant panel
less bad fear -- -and specif
continu pick increment market share
implant perform along improv sequenti
us miradri revenu trend see upward bia
full-year revenu forecast
op remain one highest convict
upward estim stori reimburs tailwind
near tip point grow number tailwind
head potenti drive meaning
upsid model includ geograph expans
japan step dtc new indic
pediatr w/ syndrom -- -all like yield increas
sale momentum within ntm specif
contempl forecast wouldnt surpris
see grow vs estimate
doabl see sequenti revenue increas
consist average q/q increas compani
experienc past three year vs impli
us/consensu would impli upsid
anyth step-up
pronounc year past given bcb tailwind dtc
initi underway also think management guidanc
like move higher given likelihood revenue upsid
current outlook contempl much
increment impact bcb effect aug
polici tailwind suspect management
incorpor month see bcb trend
expect lowest post- blow-up
confid level result specif could less bad
fear potenti prompt ralli depress
level name follow op op
op mp order think risk-reward tilt
upsid name visibl around key overhang
continu weigh stock relat rep product execution/
improv macro/china consum
sentiment limit make tough call qtr
prefer pick group
expect beat less confid much
enough definit sustain get stock print
mp mp mp list rank order rel risk-
reward trade qtr -- -in light sens expect
calibr potenti upsid print
quarter expect alc deliv rev/ ep line consensu slightli
y/i cc touch consensu revenu
adj ep believ due slightli conserv fx
assumpt within surgic expect continu momentum ou advanc technolog
iol believ us perform could benefit earli revenue contribut
physician excit trifoc len categori panoptix launch stand
benefit first mover advantag us suspect continu strong perform
cataract vitreoretin equip consum well within vision care
expect continu momentum daili multifoc contact lens
systan complet dri eye coupl earli contribut month
contact lens help off-set declin alc legaci daili
aquacomfortplu dacp contact lens contact len solut think management
like express confid upper end revenu growth guidanc
y/i cc given earlier-than-anticip panoptix approv qtr remind cc
contempl continu end-market growth surgic market rate slightli
market growth vision market rate profit think management
reiter core oper margin due increment fx headwind core
effect tax rate part model y/i cc revenue growth
upper end compani guidanc rang core adj ep project
contempl core oper margin
stanc recent initi coverag alc mp rate link believ
spin-off work spin-off novarti independ management freer
make decis better reflect long-term market opportun push oper chang
time drive growth acceler margin expans leverag ep growth
certainli lot like alc msd ophthalmolog end-market think
 spin-off enthusiasm alc share trade ep
large-cap med-tech peer group average pt appli multipl
average current multipl ep get construct
stock wed like either see pullback share greater
convict near-to-intermedi term upsid vs base case rev/ep assumpt
cc rev/ep compound-annual-growth-rate believ estim alreadi contempl
reason success launch share gain contribut us at-iol segment
alc current valuat alreadi give credit assum growth momentum like
even embed expect upsid vs consensu panoptix launch
equipment/
alc ep in-lin modest cc upsid product
track market perform
quarter expect investor come away increas confid number dont
re-set lower view top- bottom-lin grower
face china headwinds/stepped-up na clear align competit --
share begin recov depress level least degre toward
pt believ even modest rev/ep upsid could met sigh relief
long key focu area -- -i na case start case start especi china
trend -- -are in-lin better expect guidanc bracket
consensu management still see revenue long-run growth potenti margin
wors track pick sequenti help allevi concern
algn margin profil structur risk face rise competit headwind
normal wed say bar higher vs basic in-lin result sign stabil
given pullback stock trade ev/sal ep
believ market alreadi discount growth profil
model na case start reflect comp-adjust acceler
q/q improv consist management commentari expect momentum
season stronger teen capabl offset increment potenti
headwind relat competit pressur patient cohort dtc
smiledirect club sdc option impact result think management made everi
effort dial-in much conservat could issu guidanc last qtr
includ conservat reflect pressur dynam respect case
start admittedli visibl china trend limit come whether
management appropri handicap china consum sentiment headwind recal
call management indic juli china case shipment show initi uptick vs
weaken trend -- -whether trend continu remain seen
view sign stabil china and/or region acceler fast
enough pace off-set increment china deterior would go long way toward
help remov stock overhang investor like also look anoth qtr
stanc op-rat view remain unique-in-healthcar
growth asset capabl sustain least rev/ep compound-annual-growth-rate
penetr under-penetrated ww clear align market think
earli assum fundament structur chang algn lt above-avg growth rev/ep
trajectori increment uncertainti rais softer china consum sentiment
 intensifi na competit dtc offer china market larg
significantli under-penetrated area feel competit pressur
 age bracket na could prove transient natur repres smaller
part market vs teen tween meat na market opportun
growth trend remain robust clinic valu strongest
quarter expect deliv revenue least line
our/consensu estim reiter latest guidanc
revenue rang assum flat y/i rep product
upper end rang y/i declin midpoint would impli y/i
product growth deterior vs current
model feel like deceler rep product trend
conserv case management chose factor midpoint rang
attempt bake cushion number call management indic rep
product growth trend qtr behind management origin plan
matter product reacceler qtr ahead
model midpoint y/i direct rep product growth deterior
vs slightli improv
turn flat listen tangibl evid axgn
effort improv y/i trend rep product take hold
stanc maintain op rate view compani
forecast revenue growth coupl above-avg gm profil
mispric current valuat level ev/sal concern
relat execut increas competit axgn ultim total
address market size bake stock point least
larg extent said recogn management show-m mode
believ compani need deliv sever quarter row meet/beat
rel consensu guidanc re-gain investor confid biggest
concern axgn growth deceler trend past qtr
multipl guidanc re-set may relat sale forc execut
perhap someth structur concern compani end-
market and/or potenti smaller-than-expect believ mgmt
recent guidanc attempt conserv achiev
increas confid number dont need keep re-set lower
believ investor gradual begin give credit higher multipl
initi focu outperform
quarter expect meet consensu rev/ep estim
y/i cc slightli consensu rev/cc growth line
adj ep think key focu area call rev/ep guidanc
mgmt expect around revenue growth driver driver similar
ex-lutonix paclitaxcel drug-coat balloon dcb market dynam whether
management continu expect sale reduct carri forward potenti
path forward lutonix below-the-kne btk pma approv management indic
earn call fda notifi pma approv clinic
evid provid work collabor path forward submiss
updat potenti strateg option consid diabet path
pump initi management indic withdrew fda applic base feedback
receiv fda earn call respect guidanc suspect
management like issu revenue growth cc rang would bracket
our/consensu low end rang adj ep guidanc rang
would bracket our/consensu reflect rep
growth midpoint guidanc suspect management reiter confid
underli growth part biz counter potenti dcb impact keep
grower top-lin dd grower bottom-lin near-to-intermedi
term part peripher intervent pi revenue reflect lutonix
sale reduct due uncertainti around long take market rebound/
improv btk revenue due uncertainti around time btk fda approv
stanc appreci bdx mid-singl digit top-lin growth dd low-to-mid
teen fx neutral adj ep growth repres stabl less riski way invest large-
cap med-tech prefer name large-cap med-tech univers offer
one compani main growth engin lutonix suggest us overal investor
percept safer invest given diversifi sale mix bard-rel
ep synergi cushion stock still seem shrug lutonix btk
concern still think uncertainti around import growth driver limit upsid
potenti number pt assum trade slightli large-cap
med-tech diversifi peer average get construct
name like greater convict upsid potenti bcr synergi
forecast and/or better visibl regard lutonix growth prospect order argu
larger premium large-cap med-tech diversifi
quarter expect deliv revenue beat vs consensu --
street -- -a believ street conserv gen surgeri
growth compani beat multipl qtr row
bigger question view whether op margin out-performance qtr
satisfi believ fairli elev expect alreadi meaning
acceler profit growth start management indic
compani better posit drop revenue upsideshould materi
rel mgmt guidanceto bottom line least bigger way vs
play past invest year saw margin upsid
-- -relat better expect buffalo filter bf integr bf margin
upsid could store though suspect increment fx
headwind might off-set margin overag bf rel our/consensu
op margin forecast y/i -- -or least greater extent vs last qtr
also believ management want continu re-invest busi
would like manag reinvest revenue upsid mid-to-high teen ep
growth rate impli guidanc even sale upsid situat rel
compani org cc revenue growth guidanc could support someth
higher believ surgeri growth fuel buffalo filter
out-performance airseal momentum correl robot surgeri
trendsand think momentum remain strong org revenue growth
continu strong trend upsid materi think management could increas
full-yr revenue guidanc like prior qtr revenu strength asid think
management remain conserv ep outlook given strengthen
stanc -- -now sever year turnaround -- -ha clearli made
progress acceler revenu growth consist double-digit earn
growth lot go right view plu like
bf acquisit acceler margin ramp valuat
keep us mp-rate believ compani alreadi get credit
margin step-up unfold result bf project org
cc/hsd pro-forma growth profil part would like see evid
acceler revenu fact translat meaning higher oper
earn power order argu put new money work level
said think stock approach pt organ revenue growth
show sign acceler and/or margin continu beat expect
quarter expect elgx deliv revenue least line
estim roughli line consensu current forecast
loss better consensu wed note
consensu rang includ wide varieti estim suspect
out-performance materi would like come us led
afx stabil sequenti q/q ovat growth expect management
continu air conserv side reiter revenue guidanc
least heel contd sequenti improv us
ovat revenue return growth stabil us revenue
model revenue cc y/i
consist management busi strategi return above-
market growth think management also reiter opex guidanc
cash burn exit cash burn
call well listen updat select busi segment
commentari around qtr expect potenti updat
time eu ovat alto launch color around expect
us recal management indic approv delay earli vs
call clinic updat relat eva enrol
expect complet year end cheva expect earli
potenti new learn partnership china announc
stanc maintain mp rate elgx view still
show mode execut improv evidenc
perform believ still like take sever qtr improv
execut fulli regain investor confid health busi
 nellix clinic progress us ovat alto approv delay
earli vs think need posit develop
accord start see stock move sustain higher
meantim expect elgx share could continu volatil around
pt
elgx anoth step forward evolv turnaround
quarter expect least meet beat our/consensu revenue
y/i cc organ cc organ sell day adj ep think
us core spine area upsid though expect less order magnitud
upsid qtr -- -at least compar degre upsid surpris play last qtr
saw blow-out us core spine perform given compani
even tougher biolog comp qtr recal began deal
biolog sale disrupt due late-in-qtr fda warn letter biolog divis
believ quarter lead experienc particularli strong
biolog perform thu cycl strong biolog revenue prior year period
warn letter impact product still yet back market best
knowledg still expect us core spine momentum visibl result strong
competit rep recruit increas robot implant pull-through us core spine
growth project excl extra sell day lower
y/i comp point tougher hsd growth would reflect steadi growth
trend comp adj basi acceler step-up began earnest
robot project ww revenue us ou placement roughli line
consensu reflect q/q slowdown vs season weaker qtr capit
growth step given order pull forward model
vs expect nomin amount trauma revenue increas
vs remain track achiev full-year
guidanc believ management like increas revenue outlook upsid
ebitda margin like remain pick vs
compani continu spend new product compani showcas one
project new c-arm/o-arm navig robot interbodi indic nass think
anoth below-trend ebitda margin toler investor given
continu evid spend go toward item yield
increas payoff futur
stanc long suggest us core spine remain acceler trajectori
trauma sale near inflect point head think stock
continu grind higher view sustain hsd low dd revenue growth
next sever year also sustain industri lead ebitda margin
dd profit growth number key potenti multi-year growth driver start
converg -- -robot trauma us core spine growth accel growth re-accel --
stock start move beyond trade qtr-to-qtr robot placement trend
acknowledg lumpi tough predict think expect calibr
appropri season downtick robot placement qtr estim
achiev conserv
first order analyt consensu aug calculated/impli base foa
medic suppli devic survey highlight market share gain
potenti spine robot player
quarter expect deliv revenu our/consensu estim
estim in-lin guidanc believ guidanc
attempt bake conservat leav room upsid see y/i
q/q margin improv -- -due improv product mix absorpt benefit new
product sale on-going cost reduct effort -- though less confid
margin/ep upsid potenti area compani fallen
short expect multipl qtr row also fx headwind intensifi
intra-qtr could weigh margin expans improv qtr we/consensu
model y/i organ sell day adj revenue growth wed surpris growth
doesnt trend upsid rel expect like come
us breast and/or diagnostics/blood screen view
play last qtr medacorp utilization/cap-ex survey
show higher respond plan spend vs less digit mammo
equip compar prior survey increas confid upsid
potenti breast health revenue estimate especi continu capit
technolog upgrad add-on grow tomo instal base
listen potenti updat improv macroeconomic/polit challeng seen
latam mostli impact bh last qtr expect in-lin gyn result medic
aesthet season weaker aesthet qtr medic aesthet show sign
corner turn expect return ive y/i growth model
expect management issu org revenue growth guidanc rang
would bracket our/consensu forecast ep think
management issu rang captur consensu svbl toward
midpoint project bh growth rang accel vs recent
higher growth acquisit turn organ qtr model growth
molecular diagnost suspect management bless msd-hsd growth
outlook divis gyn project project y/i project
stanc remain encourag acceler growth trend within
two largest divis diagnost bh well potenti futur organ
contribut recent strateg tuck-in plu sign corner turn cyno/gyn
divis -- -all gradual help drive top-lin closer msd level
prospect excit us thu stay mp-rate without higher level
confid leverag ep growth potential/upsid bigger-than-expect
 cfo lunch focus mgn expans oppti
quarter expect beat our/consensu revenue
think expect beat abl satisfi elev
expect estim touch consensu view bake
consider conservat explicitli factor increment contribut
bcb reimburs tailwind dtc impact like start show
meaning way vs plain old conservat part
thu high confid upsid potenti qtr wouldnt surpris
see grow vs estimate would note
see sequenti revenue increas -- -consist average q/q
increas compani experienc past year vs impli
consensu -- -thi would impli upsid vs our/consensu
think anyth step-up pronounc year
past given bcb tailwind dtc initi underway expect focu
deceler prior author pa trend convers management link
leav us less concern metric increasingli becom underst
less reliabl given pa submissions/ approv track compani dont
captur physician submit directli insur vs insp market access team --
-direct submiss rise commerci insur adopt posit coverag
polici think management guidanc like move higher given
likelihood deliv revenue upsid vs consensu current outlook
contempl real impact bcb polici tailwind effect
aug suspect management updat month
belt see bcb trend go gm guidanc suspect
management minimum reiter rang
stanc remain op-rat view reimburs tip
point lead acceler adopt upsid potenti near long
term forecast addit head see grow number tailwind
insp back sever area potenti drive meaning upsid
model includ geograph footprint expans japan step dtc
initi new potenti indic pediatr w/ syndrom -- -all
like yield increas sale momentum within next month specif
contempl forecast recogn high multipl stock trade
ev/sal premium revenue vs high-growth med-tech peer
believ premium sustain given insp faster top-lin growth prospect
compound-annual-growth-rate vs peer above-avg gm profil vs
average peer big upward bia our/consensu estim
 leadership seri tailwind back seem
medic suppli devic aao-hnsf wrap-up inspir
time medicar front outperform
quarter expect anoth oper solid quarter mark out-performance ww
system procedur growth system level level --
baselin expect view whether beat key metric translat
rev/ep upsid depend proport system place oper leases/ trade-
ins/multi-system deal expect ww/u op leas increas vs
higher expect placement purchas
outright vs think could meaning upsid rev/ep
import metric view procedur expect exceed
our/consensu estim think growth achiev would like
consid enough beat long us growth trend stable-to-acceler
us gen surgeri commentari focu last qtr management call still solid though
slightli slower growth trend vs hernia colorect off-set increas
contribut growth bariatr cholecystectomi pancreat liver case management assert
slow hernia colorect growth function institut bump access
issu robot thu well listen management view rep product train effort
gen surgeri improv impact surgeon access system
procedur see growth re-acceler think investor extra sensit growth
acceler deceler -ve us procedur volum qtr term
stock would react overal procedur perform model us procedur growth
would reflect comp-adj y/i acceler vs last qtr
focu degre last qtr view believ long
system trend within average svbl
ep expect meet beat consensu magnitud ep upsid
like lower prior period given acceler invest year
sg clinic develop front recal management guid opex growth outlook
see signific futur growth opportun china india informat henc
y/i op margin project declin ep op margin assum op-ex
spend growth vs vs consensu account street ep
acknowledg could prove conserv expens evenli distribut b/w
stanc believ rev/ep estim need upward bia stock get full
credit oper beat procedur system margin
expect anoth qtr upsid think investor understand ep growth mute
given stepped-up invest spend management commentari close watch
believ investor need feel confid leverag ep growth acceler potenti
current model given competit like still year
away us launch think stock sustain upward move oper
metric beat rev/ep estim move higher post
medic suppli devic -- flash robot initi
quarter expect roughli in-lin possibl even slight upsid vs consensu
rev/ep revenue upsid materi qtr like view come
us core spine think flow-through margin bottom line would limit
compani firmli invest mode especi progress robot
platform unveil nass also expect management give color margin
think compani emphas op margin expans weight out-
year lrp provid aug investor expect y/i improv
next year might tune best guess slightli
consensu current thu think y/i street margin estim could
gravit downward come
face tougher y/i comp qtr differ divis vari degre
tailwinds/headwind view optimist potenti us core spine
upsid vs model check nass suggest single-posit later
procedur gain steam nuva solut market lead solut
like continu pick help fuel us core upsid vs
consensu last qtr well compani tougher y/i comp us core spine
wouldnt surpris comp-adj growth hold steadi would
suggest upsid y/i us core spine growth vs our/consensu estimate
less confid upsid potenti consensu revenue
continu model deceler growth trend less clear us chang
growth trajectori expect in-lin us surgic support see growth
acceler qtr lot depend whether biolog turn posit qtr
follow stretch neg growth perform
regard robot learn north american spine societi nass management
expect suggest fda approv could
event soft launch full launch also keep eye
whether initi pulse/lessray revenue might start see revenue recognit flow --
estim puls system place field yet see revenue
stanc like roadmap outlin compani analyst day
key question well nuva new management qtr execut
wed like see visibl sign margin improv top-lin acceler driver
pois inflect earlier lrp horizon justifi give stock credit
higher multipl out-year upsid potenti said us core spine
demonstr acceler vs last qtr -- -all els equal -- -the stock like move
higher toward pt
quarter expect beat our/consensu y/i
to-improv -- -even wake neg media attent
accompani may fda breast implant panel less bad fear -- -and
specif continu pick increment market share stabl
market backdrop base feedback remain confid deliv anoth
dd y/i breast implant perform growth acceler
estimate vs also expect improv sequenti us miradri
revenu trend see upward bia full-year miradri
revenu forecast dtc initi see increas payoff
ww miradri model revenue y/i reflect q/q sale typic
improv us counter normal season heel rise dtc effort
capit experi normal season dip vs think
consum growth forecast us ou could prove conserv
may sourc upsid rel think qtr past
stanc show-m stori howev one attract risk-reward
profil view believ compani deliv growth project
result higher valuat vs current depress level believ lot
breast implant uncertainti alreadi price stock continu believ
current valuat ev/sal discount group disloc
compani growth prospect acceler potenti
see upward bia full-year revenu
 solid miradri breast rais
confid growth outperform
quarter expect least meet possibl beat org growth estim
y/i con y/i like stand one best large-cap revenue growth
perform med-tech view expect beat rais top line
think comp-adj growth acceler like bogey satisfi elev expect
cc y/i upsid vs street seem achiev us consid new product launch
momentum driver endoscopi camera well trauma/extrem
suppli chain issu resolv sale upsid materi think gm/ebit mgn/ ep
could see out-performance vs gm/ebit mgn expect bigger
outlook rais potenti organ cc revenue growth side vs ep assum beat given fx
headwind intensifi sinc potenti limit ep flow-through
management like reiter least y/i op mgn ep rang
current assum unfavor fx impact expect impact go also
expect investor focu call around recent incl complet mobiu
imag llc fit spine portfolio potenti work mako
spine applic futur develop distribut agreement nr
patient-specif instrument psi
expect strong perform across syk busi segment relev
medsurg medacorp capital/util survey suggest slightli temper capit
spend outlook ntm period could neg implic margin
divis especi bump tough y/i comp next year
survey commentari forward-look limit implic dec budget
june budget alreadi set prior two quarterli survey suggest
gener stabl ntm capital-expenditure spend trend medsurg forecast slightli
consensu like leav room upsid compani new product launch
instrument endoscopi medsurg new product/replac cycl tend trump capital-expenditure
cycl ortho model normal season step-down volum -- -our survey suggest
stabl hip/kne util trend vs continu believ mako remain sourc
market share gain businesss knee divis project anoth above-mkt us
knee perform vs market
stanc think deliv elev expect albeit stock out-performance
print like requir revenue ep growth acceler -- -we confid
accel revenue growth potenti wherea ep growth accel might limit due increment
fx headwind long-term think continu sustain premium multipl
valuat large-cap med-tech averag believ compani remain one
higher qualiti increasingli diversifi compani large-cap med-tech univers
believ well-posit sustain upper-ti organ sales/ep growth higher
peer group average drive sharehold return given new product cycl across
divis futur accret contribut strong net cash balance/fcf allow
share buybacks/dividends/m
quarter expect least meet our/consensu report revenue forecast
rev/ep though think ex-fx growth like outperform vs
our/consensu cc organ growth expect heel urolift out-performance
svb leerink y/i believ momentum remain strong
help off-set increment fx headwind littl reason conservat
tfx comp-adj growth trend would deceler vs think y/i growth
perform could well card would reflect steadi comp adj growth
turn ep slightli consensu due conserv fx impact
assumpt underli oper perform ex-fx continu trend better-than-
expect case last qtr would like partial help mitig
increment fx-relat ep drag even fx headwind intensifi gm op
margin continu see sequenti step-up vs last qtr number invest
pulled-forward wont necessarili repeat least run-rat
fx impact margin focu manag one view management
expect fx repres full-year headwind vs origin contempl
beg year manag off-set underli biz out-performance
lower tax/int result unchang ep outlook base fx move sinc
estim tfx outlook absorb anoth addit
headwind alreadi contempl think doabl even strengthen dollar
result slight reduct management op margin outlook
b/w underli oper out-performance potenti non-op lever tax int expens
expect management reiter full-year ep rang face intensifi fx
headwind ex-tariffs/fx ep growth continu trend mid-teen
stanc remain top mid-cap pick given acceler revenue growth trajectori
leverag ep growth acceler prospect view stock
recent pullback -- steepen fx headwind concern -- creat better set-up
fx transient continu believ enough levers/driv
year period sustain hsd revenu growth deliv mid-teen ep
growth least -- -a better profil mani peer think investor look past
near-term minor fx-driven margin pressur long cc revenue growth continu beat
expect y/i op margin step-up vs level management reiter ep
outlook item think achiev like think investor
increasingli re-visit name given tfx multi-year revenue growth acceler margin
improv stori view durabl one sever noteworthi momentum
driver manta ezplaz urolift urolift japan still front
think investor continu get excit help support premium valuat
chgconsensusvariancerevenu adj sale organ growth rate ex- gross cash tax cash sale sale vascular order analyt consensu aug calculated/impli base foa wright medic group nv
quarter expect beat revenu estim
least meet consensu slightli weigh vs
consensu think account revenue estimate estimate
slight discrep vs consensu reflect slightli conserv
ramp cartiva core busi miss expect
roughli in-lin ebitda/ep think upper extrem greatest
potenti outperform consensu revenue forecast would consist prior
qtr lower extrem less confid near-term upsid
potenti saw shortfal cartiva core
 divis lead lower full-year outlook cautious optimist
management guidanc cut last quarter -- -especi given emphasi thing
get wors get better achiev attempt bake
cushion specif believ compani need like
deliv sever key metrics/reiter order increas investor confid
stori head cartiva revenue least in-lin consensu
track hit us core lower extrem least in-lin
street estimate y/i upper extrem out-performance vs
y/i consensu reiter ebitda guidanc
commentary/sign confid management dd revenue growth still card
stanc op rate think wmgi prospect drive dd organ revenue
growth intact despit newli introduc headwind lower
extrem believ also acceler potenti
cartiva lower extrem momentum improv manag eas
concern perform show dd growth possibl
believ stock recov wed note tend good trade
pull back low seemingli transient integr relat and/or sale
forc execut concern take print drive higher
level investor confid think us lower extrem upsid qtr would
go long way toward help stock recov depress level in-lin
result though would step right direct might consid quit
enough disprov bear thesi lower extrem challeng
structur natur -- -i cartiva size/product perform relat
distributor disrupt core lower end-mkt slow
deceler trend fact transient relat unanticip regrett rep
turnov situat might take qtr get stock
quarter expect meet revenue y/i in-lin
street reflect lower bar follow last qtr guidanc re-set
establish part ceo transit think estim achiev
dont expect much upsid potenti top-lin given view take time
new management /strategi actual translat improv sale execut
ep street suspect xent new ceo like priorit revenue growth
acceler may need ramp spend near-term accomplish
recal last qtr management lower revenue outlook flat y/i growth impli
vs prior impli continu y/i growth deceler trend
neg territori model y/i propel growth vs
compani continu work excess inventori build-up
model sinuva revenue hold steadi level reimburs
challeng like continu hinder uptak product offic set j-
code went effect oct wont like begin impact posit impact
earliest expect get updat next step compani drug-coat
balloon dcb initi follow announc ascend trial miss
primari endpoint neither consensu factor materi revenue contribut
product nonetheless potenti repres increment revenue momentum
driver longer case also expect updat progress sinc
obtain specialti pharmaci partner help sinuva adopt
stanc remain mp rate believ pent-up demand
new product like sinuva get reimburs real surgeon appetit exist
better altern treat recalcitr chronic sinus reimburs friction
like continu hinder sinuva ramp next quarter least think
take least long see meaning reacceler compani base busi
propel new leadership ceo thoma west appoint juli bring
promis improv overal execut continu believ new j-code goe
effect octob increment posit sinuva launch -- -a
management strategi push stronger specialti pharmaci partner vs exclus relianc
buy bill still signific reimburs challeng associ
sinuva launch easi fix view could interest turn-
around stori make move howev order get
construct stock wed like tangibl evid base busi
fact growth re-acceler trajectori greater confid offici
j-code -- -along better specialti pharmaci partner -- -can jump-start sinuva
momentum beyond current forecast
medic suppli devic aao-hnsf wrap-up inspir
 still wari growth accel prospect anoth guidanc
cut pt market perform
quarter expect stock out-performance recent month rais bar touch
higher weve accustom last qtr head print
believ deliv what need ex-fx revenue out-performance importantli
sell day adj acceler ex-fx incl sell day benefit think
heavili influenc stock reaction result face tougher y/i comp
improv busi momentum -- -post suppli recoveri -- -and potenti rosa
robot sale upsid vs conserv placement forecast think compani
handili power tougher comp especi given compani
differ defens suppli constrain posit time last year think ep like
line revenue upsid may necessari absorb increment fx headwind sinc
given management invest mode
suspect sale upsid situat management could express confid upper-end
potenti rais indic y/i org cc growth rang reiter
ep rang like given increment fx headwind intra-qtr
dont expect much increment color think management reiter expect
y/i margin expans albeit probabl someth management focus first
foremost consist revenue growth acceler current model y/i
bigger margin expans y/i
believ abl deliv anoth improv us/ww knee perform qtr
compani continu close gap market rate core implant
aid recent product launch persona cementless expect management
quantifi rosa knee capit sale expect higher level robot capit placement q/q
model unit vs along core us implant knee growth
combin total us knee growth vs less confid
spine cmf upsid potenti bone cement like continu weigh revenue perform
last coupl qtr management previous commun expect
see inflect busi unit first part probabl also listen
updat rosa tka knee feedback limit launch potenti updat
instrument enhanc rosa one spine taken back seat least
stanc repres attract turnaround stori one favorit large-cap
pick revenue growth acceler look set start take form meaning
way within next two qtr -- -mgmt expect achiev y/i cc revenue growth line wtd
average market rate month earlier initi expect think
multipl signific discount current gradual move higher appear
fairli clear path revenue growth acceler margin improv higher ep growth
move past suppli issu new product launch unfold rosa
medic suppli devic nass focus
medic suppli devic survey highlight market share
potenti spine robot player
tabl summari svb leerink estim chang
million except ep
revenu estim revenue estim unchang
ep estim adj ep loss estim increas due lower gm
assumpt slightli higher opex adj ep loss estim reduc due
higher gm assumpt slightli lower opex full year adj ep loss increas
higher magnitud qtrli chang due incorrect calcul
qtrli forecast adj ep loss unchang
revenu estim revenue estim unchang revenue estim
increas slightli reflect slightli aggress puls revenue contribut assumpt
model cc revenue growth vs prior
ep estim adj ep estim unchang adj ep
estim reduc due higher op-ex spend assumpt lower oper
margin forecast slightli lower tax rate vs oper margin
project y/i expans vs previous model
revenu estim revenue estim unchang
ep estim adj ep loss estim increas full year
adj ep remain adjust qtrli cadenc adj
ebitda ex-sbc also slightli increas vs previous
revenu estim revenue estim unchang revenue estim
increas slightli believ model rosa revenue contribut
potential/ramp model cc revenue growth vs prior
ep estim adj ep estim unchang adj ep
estim reduc due higher op-ex spend assumpt offset revenue increas
reduc margin project y/i margin expas vs
tabl summari svb leerink pt chang
base valuat elgx group small-cap market cap med-tech compani
esta elgx forecast assum y/i cc growth y/i growth elgx current trade
discount group average sale vs sale vs sale appli discount group
multipl account execut risk well chanc elgx may abl drive above-market growth nellix approv expect
month pt base ev/sal multipl turn discount group multipl elgx sale forecast use
cash posit debt account debt paydown
pt assum ev/sal appli sale forecast ev/ebitda ev/sal
ev/ebitda basi nuva valuat sit ev/sal ev/ebitda discount respect peer group
snn price-to-earnings basi trade discount peer group multipl
vs peer pt assum ev/sal ev/ebitda discount still warrant level given slower sale profit growth prospect
valuat impli discount ev/sal discount ev/ebitda discount price-to-earnings vs group averag trade
ev/sal ev/ebitda price-to-earnings respect
trade fairli steep discount large-cap med-tech group price-to-earnings average believ level discount vs large-cap peer warrant given
average top-lin growth execut risk relat zbh-biomet integr suppli issu think current discount vs peer wide
believ ultim busi time capabl gener hsd ep growth gradual top-lin acceler low- mid-singl digit
growth territori pt assum trade ep narrow valuat gap vs large-cap med-tech average
forward multipl would zbh current price-to-earnings multipl would still repres discount large-cap exclud ew
group average price-to-earnings compani large-cap group includ alc
rate alcon alc share mp pt follow spin-off
novarti alc one lead pure-play ophthalm devic compani ww
sale support lead posit end-market grow msd within
surgic vision care arena overal believ spin-off work management abl
make decis better reflect long-term market opportun push oper chang
time drive growth acceler margin expans leverag ep growth although
lot like alc end-market stori think current valuat
enthusiasm alc share trade ep large-
cap med-tech average ex carl zeiss ew get construct stock
wed like either see pullback share greater convict near-
to-intermedi term upsid vs base case rev/ep assumpt cc rev/ep
compound-annual-growth-rate base case assum alc see revenue growth acceler
vs reflect success product launch
two key near-term product vision care panoptix
 surgic meanwhil project oper margin expand vs
compani long-term model low-to-mid profit
goal -- -help gm improv higher margin product ramp manufactur optim
occur sg leverag global busi services/sap implement sale forc
invest taken togeth msd revenue growth plu oper margin expans
look set drive ep compound-annual-growth-rate
pt assum alc trade average current
multipl ep feel alc current multipl alreadi reflect healthi dose
spin-off enthusiasm dd ep growth prospect stock price-to-earnings compar
large-cap med-tech average ex carl zeiss ew premium
like sustain view given alc above-avg oper profit growth prospect
compound-annual-growth-rate vs average group think multipl expans could
limit unless we/investor get confid top-lin acceler level
track materi faster expect alc margin expans stori materi
quickli vs expect suggest outsiz out-year earn power rel
consensu alc current price-to-earnings reflect rel premium
compani first month sinc trade began note meaning higher
healthcare/medtech spin-off situat analyz even consid widest
group average rel premium reach within month post-spin period appli
multipl adj core ep get pt
underli cataract surgeri growth vitreoretin procedur growth rate slow vs current
pullback economi custom flexibl spend could limit consum willing
pay premium eye care technolog advanc technolog intraocular lens at-
iol premium contact lens daili multifoc toric design elect surgic
procedur refract laser vision correct lasik prolong possibl
deterior hospit capit purchas trend either due economi healthcar
uncertainti could limit upsid potenti alc surgic equip consum busi
compani unabl deliv estim timelin new product expect
near-term growth driver help propel alcon revenu growth market rate
mid-to-latt part long-term plan
compani unabl capit trend toward premium technolog launch
key product panoptix trifoc at-iol daili silicon hydrogel sihi
potenti competit at-iol
surgic eye care manufactur launch compar possibl better trifoc
len us could provid physician patient altern alc first-to-market
panoptix trifoc len could limit alcon abil increas us at-iol market share
expect competit emerg time given sever trifoc avail ou
carl zeiss bausch lomb clinic trial envista trifoc len
alc unabl optim manufactur effici new contact len mfging line dsm
flex platform could limit compani abil drive gross margin improv deliv
long-term oper margin target low-to-mid alc unabl deliv
sg leverag global busi services/ sap implement sale forc invest
could limit compani abil deliv oper margin expans low-to-mid
spin-off novarti caus unforeseen custom suppli disrupt disrupt
full implement compani enterpris resourc plan erp system
disrupt manag abil execut could impact compani abil deliv
long-term goal msd revenu growth and/or low-to-mid oper margin
rate op pt see scarciti valu growth/profit profil
mani small/mid-cap med-tech compani boast prospect double-digit top-lin
growth gm op margin expans debt cash algn invisalign platform
clear align technolog grow altern tradit brace wire bracket
expect continu experi higher util orthodontist gener dentist
practition treat malocclus patient need tooth movement invisalign
ww penetr view scratch surfac long-term estim
compound-annual-growth-rate push broader deeper two key custom channel orthodontist
gener practition new product augment type case invisalign
address market promot physician train initi drive higher consum
demand greater physician confidence/adopt outreach aim teen -- rel
untap segment repres orthodont case ou expans
top-lin growth rate yield acceler ep growth on-going expens
leverag invest return buyback think out-year estim still leav room
upsid reflect revenu growth compound-annual-growth-rate assumpt low end management
competit continu forefront investor mind note eventu
step-up clear align competit noth new part continu believ
differenti materi smarttrack manufactur know-how patent protect around
recent post technolog advanc keep well posit stay
lead align market continu expand/ convert wire bracket end
day view competit valid under-penetrated categori penetr
market expansionari
pt believ trade least
lower-end averag differenti and/or monopolist technolog
larg still-underpenetr market opportun peer above-averag earn
power larg under-penetrated market expand tam compani univers
characterist ew trade p/e
respect well sale
average forward ratio average compound-annual-growth-rate project
grow top vs bottom line vs group faster
average compani deserv closer least low-end peer view
even use slightli low-end group average appli
project ep growth forecast would still suggest price-to-earnings appli
ep get us add addit
cash/shr yield pt valuat consist dcf analysi wed
also note valuat would correspond ev/sal would also
in-lin albeit low end rang average algn high-
growth peer ev/sal
risk invest thesi price target includ sensit potenti slowdown
macroeconom environ dental industri may affect downturn vs
non-elect healthcar arena patent expir begin allow competitor
access know-how could open door better cheaper altern
diminish power monopolist posit revenu growth sustain could call
question address market invisalign smaller model invest
support growth deliv lower anticip roi limit earn power
rate op pt view compani sustain high-growth
revenu grower uniqu barrier-to-entri around one flagship product avanc
high gm busi scalabl time think compani track post
growth attract growth profil combin gm
believ mispric ev/sal vs high growth small-cap med-tech
average respect -- -a level larg extent alreadi seem us account
concern around potenti increas competit sale forc execut size tam
compani well-posit sustain lead posit peripher nerv
repair also lead categori expand util larg significantli
moreov overal expand compani estim
compani begin target use product surgic manag pain
beyond adopt increas think capabl sustain least
revenu compound-annual-growth-rate compani product gener gm think
sustain enabl turn profit commerci
avail human process nerv allograft market believ key product
avanc well-posit lead paradigm shift treatment -- -especi larger gap
nerv repair -- -bi provid less invas econom attract altern autograft
current standard care requir donor site nerv harvest add time/cost
surgeri furthermor avanc enjoy uniqu regulatory/commerci situat addit
intellectu properti ip protect ensur market exclus
pt support dcf assum achiev out-year
penetr compani estim total address market close
next year next year ev/sal basi share
price would translat estim closer axgn high-
growth med-tech peer group average trade think appropri compar
select group ultra-high growth med-tech peer trade current
current trade group
averag ev/sal vs group vs group
believ discount narrow rel group ev/sal basi given
top-lin growth prospect compound-annual-growth-rate vs averag peer
above-averag gm profil vs average peer believ estim
repres base case leav room upsid
potenti slower-than-project adopt curv adopt remain
sidelin extend period hand surgeon plastic surgeon perform trauma
procedur oral maxillofaci surgeon tend slower adopt nerv repair
technolog prefer trial new product wait long-term result dive
develop degre product reorder take longer expect
convinc middl adopt clinical/econom valu proposit product could
result flatter adopt curv potenti result risk estim
new product pipeline/market expans area could take time materi recent
launch product pipelin product new market expans area still develop could
take longer materi current project model could mean downsid risk
sale ep forecast
exposur regulatori risk pursu bla lose inher
exclus avanc bla discret continu sell avanc pursu bla
could hamper compani abil enjoy uniqu commerci opportun
potenti diminish believ strong competit advantag could
ultim lead competit allograft segment bake avanc
revenu project avanc market opportun furthermor guarante
avanc bla success get approv repres potenti regulatori risk
result recon phase trial expect higher requir support
bla could result higher expens forecast assum model
price pressur could put downward pressur sale gm forecast
contempl certain degre price pressur model moder gm
time may experi signific price pressur estim assum
could put revenu gm forecast risk worse-than-expect price pressur
could materi need discount greater degre assum
integr deliveri network idn group purchas organ gpo compani
tri drive bulk order larger institut valu proposit around
portfolio avanc axoguard aviv perceiv strong enough justifi current higher
commerci execut risk compani unabl hire rep quickli project
take longer model rep come product curv could lead
slower revenu growth trajectori forecast likewis prove harder
expect requir invest model open new account and/or drive
deeper penetr exist account could repres sourc downsid risk
competit compet nerv repair busi unit part larger
diversifi med-tech compani cross sell capabl bigger resourc
current nerv repair product compris small revenue larger competitor
believ market major focu compani howev
compani increas investment/focu could result higher level competit
vs compani experienc past
continu posit bia ep step-up bcr transact provid
context volatil market bdx diversifi sale mix bcr-relat ep synergi
cushion may view rel safer invest potenti limit stock downsid
howev name large-cap med-tech univers prefer
offer upsid potenti pt assum trade premium large-
cap med-tech diversifi peer given above-averag ep growth potenti get
construct name like greater convict upsid bcr synergi forecast order
argu bigger multipl premium large-cap med-tech diversifi vs current
pt think compar larg diversifi
med-tech peer group given exposur across medic technolog life scienc
peer group includ trade ep among
group rev/ep growth profil average correspond
price-to-earnings multipl meanwhil cc revenue and/or ep growth profil
correspond price-to-earnings multipl think trade
premium lower bound rang discount upper bound
appli price-to-earnings ep get us pt
risk valuat includ accret estim bcr prove overli conserv
aggress fx volatil signific exposur emerg market revenue growth
volatil slower-than-anticip uptak compani diagnost
long term believ organiz changes/new product continu take
form posit continu gener msd least top-lin growth
improv margin profileth latter margin improv slow evolv despit
improv former top-lin acceler last quarter refresh
chang period choppi time-frame mark acceler
revenue growth earli sign oper margin expans remain optimist
buffalo filter bf transactionclos help drive addt cumul
margin expans vs current estim make happen faster
otherwis might materi also believ get credit
margin step-up least extent premium multipl alreadi thu remain mp
rate pend greater confid acceler revenue execut bf deal integr and/or
underli fix cost leverag base biz fact begin translat outsiz out-
year op earn power vs current forecast order argu put new money work
level
pt pt base ev/ebitda appli
ebitda current trade premium peer group ev/ebitda vs
group premium price-to-earnings vs group
discount ev/sal vs group argu histor
turnaround situat inwher long-term revenu ep power
potenti underst revenue growth acceleratinga higher-than-group average multipl
justifi especi ev/ebitda price-to-earnings basi pt assum
turn premium group ev/ebitda ebitda forecast
peer group includ med-tech compani either compet similar end-market
similar type stock characterist
snn demonstr abil consist execut
 beat consensu acceler organ sale growth faster project deliv
commensur oper ep upsid process believ could room
multipl eventu trade wider premium group ev/ebitda basi primari
valuat metric howev without convict even great upsid potenti out-year
ebitda ep forecast troubl argu bigger ev/ebitda multipl premium
point time
multipl expans margin expans prospect heavili depend cnmd abil
acceler sale growth margin expans stori heavili depend sale
growth acceler thu initi take longer expect end market begin
slow unabl drive better perform exist portfolio could
caus revenue/ebitda forecast risk convers faster expect sale growth
acceler model could lead higher rev/fast profit think
cnmd turnaround could take longer forecast requir heavi lift
expect abil jump-start sale growth could involv reassess
exist busi divestitur could lead near-term disrupt model
put forecast risk
execut new product launch may success past fit
start new product launch includ delay redesign new product launch edg
perform poorli could neg impact percept customers/investor
compani turn corner
capit equip market cyclic cnmd exposur mostli smaller ticket item rather
multi-million dollar equip said ebb flow capit purchas
could nevertheless affect compani hospit administr re-priorit resourc
alloc away cnmd product could neg impact sale growth
 dilut could neg impact margin expect small tuck-in
absorb compani oper structur limit impact possibl
manag may pursu larger deal pursuit long-term object could
neg affect margin near term similarli groom portfolio divest
asset could also neg impact near-term sale growth profit
rate endologix market perform pt elgx largest abdomin aortic
aneurysm aaa pure play hold market share posit us
ww aaa market per compani report us nellix approv potenti
event year delay vs prior expect think investor increasingli focus
turnaround exist platform afx ovat ceo onopchenko appoint
may initi busi re-set end aug /begin sept in-depth
evalu busi compani outlin three phase next year
analyst day aim improv commerci organization/strategi stabil
busi long-term goal return above-market growth profit came
away increas confid wheel come bu still wait-and-
see execut stori view near term believ price appreci prospect
next month tie compani abil execut guidanc remain
sidelin see potenti sourc drive upsid estim given elgx
bigger catalyst growth re-acceler weight take sever qtr
us believ investor get comfort compani abil execut
base valuat elgx group small-cap market cap med-tech compani
elgx forecast assum y/i cc growth y/i growth
elgx current trade discount group average sale
vs sale vs sale appli discount
group multipl account execut risk well chanc elgx may
abl drive above-market growth nellix approv expect
pt base ev/sal multipl turn discount group multipl
elgx sale forecast use cash posit debt
account debt paydown
nellix repres key growth driver elgx compani cant secur fda approv
nellix approv delay out-year forecast could risk think afx/ov could
recaptur part unreal nellix revenu case anoth delay commerci
nellix us repres largest sale growth driver compani possibl
addit delay nellix could drive surgeon use elgx devic trial
risk limit portfolio breadth beyond aaa
elgx play sole aaa space compani abil servic institut
look consolid purchas across cardiolog servic line limit
hospit administr decid consolid purchas larger organ
elgx abil get shelf exist account penetr new account
could limit
elgx potenti acquisit target upsid risk price target
nellix opportun larger anticip manag demonstr
double-digit revenu growth ramp profit think elgx could repres
attract asset potenti acquir think acquir appetit differenti
small cap med-tech growth asset nellix appear fit bill sentiment around
name begin contempl takeout valuat could sourc upward pressur
vs price target
rate op confid multi-year hsd top- dd bottom-
line growth stori sustain revenu growth trajectori hsd low-teen
y/i project heel emerg new product cycl robot
 trauma get underway view number key lt driver
come place -- -trauma us core spine growth acceler core spine acceler
new robot indic horizon acknowledg might take
stock get credit driver think potenti manifest
significantli within time frame becom increasingli evid robot implant
pull-through grow instal base excelsiu system acceler core us spine
growth sustain hsd territori increment revenue contribut gmed push
trauma begin materi expect investor confid durabl recur
revenue aspect gmed dd revenue growth stori begin get attent vs quarterli robot
placement lumpi unpredict conjunct gmed low-
ebitda margin profil one best med-tech sustain view
lead gradual multipl re-expans compani lt revenue goal sale
would impli signific upsid us consensu think also factor capit
deploy toward growth/accret buyback enjoy healthi net
cash posit end
pt assum trade ev/ebitda premium peer
current ev/ebitda average current trade
ev/ebitda repres discount group assum group multipl
hold see multipl move back toward group average
appli ebitda forecast get us even think
premium justifi would upsid pt boast margin profil
almost higher peer group averag believ top-lin growth
rang sustain time-frame vs peer group average hsd
risks/uncertainti includ spine market pricing/volum pressur produc
bigger than-expect slowdowneith due increas insur pushback weak economi
and/or broader industri price pressur spread minim invas surgeri mi
spine product offer could put pressur gmed sale growth opportun
compani robot trauma product pipelin could take longer expect gain traction
gener revenu new rep hire recruit initi take longer expect
drive higher rep product and/or improv compani core us spine busi
could put gmed growth acceler trajectori risk caus improv y/i organ
growth take longer project materi integr continu
gener momentum struggling/slowli improv busi could put
ou sale growth acceler estim risk higher level reinvest
weve alreadi contempl model requir sustain top line could caus
gmed ebitda margin fall level could limit gmed ev/
rate share market perform pt convict near-term ep estim
upsid diminish -- -especi tax-benefit- relat ep cushion
basic get use mitig reduc sale outlook lower cyno
expect cyno compani achil heel sinc acq close
begin question whether busi struggl might structur
natur vs pure sale forc execution/backfil management assum meanwhil still
struggl gyn franchis also turnaround time uncertain recent fda focu
marketing/ind women health product monalisa touch add grow set
headwinds/uncertainti ultim view tough end-market rate stock
mp pend greater confid ep upsid potenti cyno number begin
move need come and/or organ cc revenue growth sustain
move back msd territori faster expect
pt base multipl appli ep given improv
underli perform ex-cyno driven strength bh continu improv us
molecular diagnost gyn think multipl continu expand depress
level close valuat gap peer current trade price-to-earnings howev
still think discount group appropri given current slower top-lin profil
vs cyno busi remain challeng appli
get us appreci stock cheap rel basi price-to-earnings
discount peer also think share could remain range-bound given lower
confid ep upsid potenti could limit near-term opportun multipl
peer group use blend select med-tech capit equipment/imag
comp group current trade averag forward price-to-earnings multipl
current trade ep
ev/ebitda basi trade peer group
average pt would impli ebitda still
risk valuat includ us hospit administr pull back capital-expenditure
invest could caus delay holx capital-expos busi within breast health
tomo affirm unabl execut cost-synergi goal -- -or cyno integr
effort gener prove challeng expect -- -thi could make harder
achiev sale growth ep accret assumpt thu ep estim
produc enough increment growth tailwind off-set eventu slowdown
beyond tomo cycl could put out-year estim risk
rate op dcf-base pt believ compani sustain ultra-
high-growth top-lin grower innov treatment altern moder sever
obstruct sleep apnea osa high gm busi scalabl
time first fda-approv technolog kind well-posit
lead paradigm shift moder sever osa treatment toward minim invas
neurostimul therapi larg under-penetrated svb leerink-estim us cpap
total address market separ potenti low hang fruit oppti sleep
apnea surgeri could repres us think compani capabl
sustain least revenue compound-annual-growth-rate -- -well average revenue growth prospect
high-growth med-tech peer -- -a adopt increas view key driver adopt
trajectori includ reimburs coverag expans think reimburs
friction near tip point aetna cover procedur bcbsa
evid street issu posit summari sale forc expans focu
deeper penetr exist center new account grow awar inspir
therapi clinic real world data build reimburs could sourc upsid even
above-consensu growth forecast alongsid sever area arent specif
contempl model geograph footprint expans uk belgium
new indic pediatr syndrom high-growth profil complement
best-in-class gm view sustain forese futur
enabl turn profit
pt base dcf assum achiev base case out-year
penetr estim us cpap market opportun vs
smaller low-hang fruit us osa surgeri market opportun vs
support ev/sal multipl analysi ev/sal basi share price would
translat revenue think appropri compar
select group ultra-high-growth med-tech peer trade current
irtx current trade
premium vs sale believ insp premium
justifi widen given faster top-lin growth prospect compound-annual-growth-rate
vs average peer ex average sustain gm profil vs
average peer upsid potenti our/consensu forecast -- -a believ
leav room upsid
addit reimburs coverag take longer materi could limit
upsid potenti adopt trajectori reimburs coverag key factor consid
evalu insp potenti adopt trajectori annual revenue growth coverag
decis take longer materi current project model beyond
could present downsid risk sales/ep forecast could meaning impact rate
abl penetr estim cpap market opportun
competit osa neurostimul devic first fda approv
neurostimul devic moder sever osa patient awar two
competitor neurostimul solut develop imthera/livanova nyxoah
competit show posit potenti better clinic result could provid patient
physician better perhap less expens altern inspir system
could put insp adopt trajectori risk part think earliest potenti impact
competit imthera like least year away possibl impact inspir
adopt trajectori if/when approv may limit mere market expansionari
unless competit system show better data vs insp robust data
given insp year experi navig challeng reimburs landscap
commerci execut risk compani unabl hire rep quickli project
take longer model rep come product curv could
lead slower revenue growth trajectori forecast likewis prove harder
expect requir invest model open new account and/or
drive deeper penetr activ center could repres sourc downsid risk
sales/ep forecast and/or lengthen op leverag prospect timelin profit
long-term clinic data year result futur long-term data
yr show compromis patient health qualiti life daili hypogloss nerv
stimul could potenti derail insp adopt trajectori repres downsid risk
sales/ep forecast check medacorp specialist suggest physician
hesit adopt inspir therapi long-term impact beyond yr daili
hypogloss nerv stimul unknown part believ highli unlik
signific drop-off reduct osa event inspir given trial
consist shown reduct year check continu highlight
inspir procedur econom incent physician particularli compel
procedur could limit pace adopt compani move beyond
earli adopt phase even though physician make money procedur may less
like adopt procedur least may acceler util rapidli project
physician end econom sensit expect respect current
medicar payment commerci payment relat
procedur payment amount inspir cover increas and/or procedur
time eventu reduc possibl could eventu repres limit factor
procedur uptak compani move beyond academic-ori earli adopt
phase -- -to extent factor dont outweigh/influ physician behavior beyond
pull effect potenti pressur physician offer might otherwis lose relev
rate share outperform ultim believ key valu driver
place stock work intermediate-to-longer-term acceler
procedur growth new product cycl momentum continu uniqu robot
colorect bariatr thorac head neck other acceler growth procedur
adopt intern dvp da vinci prostatectomi europ japan addtl procedur
reimburs china new quota new product cycl xi sp ion help
sustain above-averag top- bottom-lin double-digit growth system advanc
continu open increment surgery/revenu sourc time shape
invest year origin anticip surpris management
want dial reinvest time two back-to-back new product cycl sp
 flex cathet robot line sight multipl lt develop opportun
expans china india informatics/ai surgeri initi expect stepped-up
invest ultim enhanc market leadership posit expand surgic
robot categori potenti increas payoff out-year also continu
believ sustain uniqu large-cap med-tech mid-teen revenue growth least profil
complement mid-teen better ep growth compound-annual-growth-rate
valuat base dcf analysi yield pt discount rate
calcul use capm model current trade price-to-earnings ex-cash
basi incl cash ex-cash incl cash vs broader market
cap med-tech average incl ew pt
impli appli adj ep less int incom cash believ
isrg premium group sustain given above-averag top- bottom-
line growth compound-annual-growth-rate potenti vs peer amid multipl new product cycl help drive
increas penetr still-larg under-penetrated long-term robot surgeri opportun
risk valuat includ high volatil wide-trad rang stock
compani relianc singl product robot potenti chang wors hospit
capit spend environ continu debat around cost/benefit come
adopt robot procedur current project valuat could risk
gyn/uro trend slow greater degre model newer gener surgeri robot
procedur slower expect adopt forecast anticipated-to-launch
nexgen sp platform delay fail gain traction launch compani cant
achiev revenu contribut model flexibl cathet robot program
key risk includ ou growth slower anticip -- -either due delay
develop new japan procedur opportun and/or new china system tender/quota
newer robot entrant mdt/jnj beyond come onto
scene result competit trial potenti caus hospit purchas cycl elong
given robot solut evalu sg invest combat competit
develop new market lead greater opex spend -- -potenti limit near-term
earn power -- -v weve model
rate market perform mp pt would like greater convict upsid
potenti number and/or faster top/bottom line growth potenti argu share move
meaning sustain higher appreci leadership chang new ceo chri
barri could portend improv account consist execut eventu still
think downsid risk number nuva new ceo like want invest
busi potenti make addit personnel chang
pt assum ev/sal appli sale forecast
ev/ebitda ev/sal ev/ebitda basi nuva
valuat sit ev/sal ev/ebitda discount respect peer
price-to-earnings basi trade discount peer group
multipl vs peer pt assum ev/sal ev/ebitda discount still
warrant level given slower sale profit growth prospect valuat impli
discount ev/sal discount ev/ebitda discount
price-to-earnings vs group averag trade ev/sal ev/ebitda price-to-earnings
recent new product launch gener bigger sale momentum weve project
lead bigger share gain spine faster-than-model sale growth re-
benefit magnitud quickli weve model
us spine market begin acceler either due eas price pressur and/or less
insur scrutiny/reimburs pushback procedur believ contribut
soften us spine market recent quarter
due increas pushback insur weaken economi
sale new product launch materi slower expect due limit clinic
data reliabl issu lack perceiv clinic econom benefit provid
rep difficulti penetr new sale territori drive higher sale per procedur
recent introduc about-to-be-introduc compet spine technolog cannib
near-term market share gain above-ment risk factor would like
inhibit compani abil increas sale forc product believ would put
oper leverag ep growth potenti risk
dis-synergi johnson johnson/synth integr sourc share
gain other spine industri mdt struggl spine franchis
previou year howev mdt spine growth begun improv recent qtr
may come nuva expens likewis jnj synth integr gradual
hit stride could repres diminish sourc share gain opportun smaller
player could repres risk sale forc turnov would
increas averag level compani abl fill posit
rate op pt see under-appreci increasingli diversifi
multi-year growth acceler stori expand medic aesthet portfolio address
multipl billion-dollar aesthet end-market opportun project tripl revenu
heel us breast implant re-launch increas adopt
miradri technolog togeth believ sustain compound-annual-growth-rate least
sale estim leav room upsid believ out-year capit
expenditur consum miradri market penetr assumpt conserv moreov
factor substanti breast product contribut potenti sale
disput show-m stori howev one attract risk-reward profil
view believ compani deliv growth project result
higher valuat vs current depress level trade sever discount small-
cap med-tech peer ev/sal vs average seem us alreadi bake lot
breast implant market uncertainti relat fda panel media attent execut risk
associ miradri busi
oct suspend coverag follow ce mark suspens disrupt
manufactur facil fire sole brazilian supplier forward year today
re-launch us new breast implant line call opu us
manufactur capabl think compani stronger competit posit upon
return market result sever transact last year
broaden breast product portfolio also includ transform deal
miradri provid uniqu technolog target larg under-penetrated
company/svb leerink estimate aesthet market opportun sweat reduction/hyperhidrosi
compani bump challeng us breast implant market amid
march fda panel led neg media attent around categori slow
consultations/th underli us bi end market growth howev believ compani still
grow substanti faster market given compani share gain posit
also believ market begin stabil possibl improv move
past fda panel concernsth outcom least seem much less bad
fear
pt base dcf assum wacc long-
term growth rate debt cash balanc share count
reflect higher share count compani equiti rais base post-money
valuat use project cash balanc pt would translat
ev/sal vs current multipl trade ev/sal
discount vs high-growth med-tech peer
esta trade
ev/sal given sien above-avg top-lin growth prospect think stock
see multipl expand current depress level move toward group average
compani demonstr recaptur market share us breast implant market
beyond launch opu implant see sale growth materi
grow miradri instal base associ consum revenu -- -which would like
help valid miradri opportun fact larg includ us think could
us breast product growth re-acceler could challeng expect
follow approv opu implant abl convert prior user see rise
util exist user extent weve model could put breast product
estim risk well slow end-market us breast implant volum could also put revenue
target risk bia-alcl concern -- -surround fda adcom panel march
action fact taken fda futur -- -weigh physician consultations/pati
willing get breast implant greater extent model management
dial y/i breast implant growth outlook compani could face bigger
appreci hurdl respect brand percept and/or physician willing go
back start use given year window compani hasnt
manufactur product -- -follow manufactur issu facil fire occur
compet two larg manufactur johnson johnson allergan
two entrench compani abl provid plastic surgeon broader offer
technolog beyond breast implant lower price bundl type program
doctor decid fulfil major need singl supplier provid multipl
product addit breast implant filler botox etc could troubl make
inroad new account win back prior custom entrench
competit us breast implant segment road could make market
crowd barriers-to-entri us breast implant segment signific
suspect earliest new competitor would come market us year if/when
competitor secur fda clearanc pre-market approv pma process -- -or
somehow secur expedit clearanc -- -thi would increas number player
segment beyond current could becom harder drive higher
util breast implant also possibl new entrant choos pursu
investig devic exempt breast implant space could creat headlin risk
even achiev actual approv
potenti competit sweat manag and/or may take longer anticip
develop awar sweat manag categori on-label devic
energi substitut miradri current awar howev cant rule
possibl competitor energi modal laser rf eventu get use
market off-label separ advanc tradit sweat manag therapi
topic treatment could offer pt better option vs current avail
today -- -possibl make miradri purport benefit consid mind consum
less advantag otherwis might view dermira one
product could potenti offer pt provid better altern current topic solut
address hyperhidrosi depend extent increas pt willing deal
drawback typic associ topic might decreas pool pt potenti
will activ seek altern type therapi miradri part
think impact like minim medacorp feedback suggest even
dermira product success approved/commerci like replac
type topic treatment pt still like consid altern miradri given
topic solut still requir repetit use dermira market expansionari and/
success convert pt topic therapi limit impact miradri
potenti patient popul risk take longer expect drive increas
consum awar hyperhidrosi treatment like miradri could lead flatter
adopt trajectori contempl model given awar consum
demand item derm plastic point us gate factor purchasing/
offer technolog like miradri mindset work
balanc sheet risk compani recent equiti rais enabl grow
busi satisfi mileston payment come due sale threshold met
certain recent acquir product portfolio reason compani cash burn
trajectori end steeper model take longer reach
cash flow break even would like rais capit either debt equiti
think risk equiti dilut low right though especi light recent
rate share outperform price target remain one
higher qualiti compani large-cap med-tech univers today increasingli
diversifi medic devic compani one believ like drive least mid
high-singl digit top-lin high-singl digit low dd digit bottom-lin growth
compound-annual-growth-rate busi mix continu evolv core reconstruct
implant busi hips/kne total sale trauma/extremities/oth orthoped
implant total sale medsurg total sale neurotechnology/spin
sale next two year view one best posit compani
large-cap univers sustain upper-ti organ sales/ebitda/ep growth drive
sharehold return given new product cycl across divis help support
division sale growth rate key end-market grow exposure/market
reprocess robot on-going cost/expens optim effort expect
help yield least underli annual ebita margin expans
contribut physio-control invuiti acquisit cash
market secur total debt expect use enhanc
sharehold valu continu re-deploy toward share buyback dividend
long-term potenti gener signific sale synergi forecast out-year
estim mako platform spine extrem investor increasingli focu
sale growth factor oper leverag opportun beyond believ
stock move higher consid attract entri point
current share trade cash ep premium large-
cap med-tech averag alc
ew given averag sale growth prospect think even wider premium
warrant confid syk average sale growth sustain profit
earn growth prospect capabl track least line large-
cap med-tech peer group averag faster given potenti revenu upsid
year potenti invest erp transatlant cost initi yield
meaning oper leverag futur potenti room accret
stepped-up buy-back activ drive upsid estim given stabil compani
top-lin new product way/rec launch think trade higher
premium vs peer group average appli turn premium vs peer group average
ep yield pt
risk valuat includ prolong pullback possibl deterior hospit
purchas trend either due economi uncertainti around limit upsid
potenti medsurg estim unabl gain hundr basi point market
share result total knee launch mako system -- -or adapt mako system new
ortho indic deploy cash possibl dilut acquisit new
product launch robot success forecast gener
increas sale momentum unabl deliv oper leverag and/or dd
ep growth despit sustain above-averag top-lin growth rate
outperform rate pt light recent neotract acquisit
see clearer pathway toward hsd org sale growth rang
vascular solut vsi close feb neotract close deal
organ mix strong record execut come integr
includ under-promis over-deliv initi synergy/sal target
less near-term cost synergi potenti associ neotract top-lin accret
potenti excit us deal believ potenti transform
hsd revenu grower out-year also think could addit sales/
ep momentum out-year factor model consid increas
contribut neotract ou market bulk exist urolog footprint
current sit urolift today minim presenc eventu revenue contribut
increas revenue contribut manta acquir essenti medic acquisit
pma approv potenti futur tuck-in addit restructur
opportun addit program alreadi underway project earn power
ep compound-annual-growth-rate op margin expans potenti given
confid top-lin acceler territori mid-teen ep
growth profil -- -both upper-end peersw think sustain
current premium group assum multipl ep suggest
trade ep slight premium versu
peer group hospit suppli compani compani relev
trade ep given confid top-lin acceler
hsd territori margin expans driven acceler mid-to-high teen profit
growth profil -- -both upper-end peersw think fact widen
premium group appli multipl premium group
ep suggest pt wed note compani med-tech msd-
valuat could risk new product launch organiz improv effort
planned/prior integr synergi cost-cut effort prove challeng take longer
expect implement neotract acquisit integr time fashion
reason uptak compani urolift platform materi quickli
project could put pro forma sales/ep forecast risk well tough competit
larger hospit suppli compani could hinder abil make inroad new
product launch hospitalsin effort rein cost preserv profit given numer
global macroeconom challeng uncertainti relat political/healthcar reform tighten
belt grow less will negoti price hospit suppli product could make
harder drive higher product compani typic sold
discount market rate attempt bring market rate newli launch
achiev sustain price increas key driver long-term gross/oper margin
improv instrument order achiev long-term sales/profit goal
discret item neg impact organ cc revenue growth compani base busi
prove transient take longer resolv expect would like damag
management credibl decreas investor confid org revenue growth acceler thesi
key part invest thesi
op-rat ultim believ continu take step help
sustain compani posit market leader fast-growth extrem segment
moreov wmgi/trnx combin view creat attract uniqu mid-
cap growth extremities/biolog asset broad reach across three fastest-grow
ortho market shoulder foot ankl biolog believ stock move higher
investor new exist re-focu health trnx still-rapidli grow
end-market enhanc posit within themespeci augment inject
approv use select foot ankl procedur sustain long-term double-
digit revenu growth margin expans prospect upsid potenti estim
pt appli ev/sal multipl revenue forecast in-
line average small-cap med-tech peer
trade ev/sal average revenue growth prospect despit
high leverag ratio believ dd top-lin growth prospect gm
profil fetch multipl least in-lin peer group ev/sal multipl especi
consid end-mkt among best med-tech let alon ortho
grow hsd think acceler potenti toward rang
cc ev calcul assum debt cash
balanc gener off-set cash
price target could risk key invest turnaround initi prove
difficult take longer expect yield hoped-for result gm improv improv
cash flow higher sale rep product faster extrem growth etc recent rep hire
lower extrem segment yield hope payoff see rise product rate
time fashion and/or competit pressur smaller privat own physician own
player wors anticip shoulder market experi deceler
growth cartiva smaller project compani effort train docs/driv
higher adopt materi expect product liability/litig claim result
advers legal outcom requir pay larger anticip cash settlementsbeyond
amount alreadi reserv settl
think differenti solut uniqu steroid-elut implant technolog
propel fda-approv devic kind treat chronic sinus cs
sinuva launch in-offic product tap even larger pool patient visit ent
in-offic manag cs pre- post-surgeri refractori combin estim
product help access increment annual market opportun howev
access sinuva product prove challeng anticip
issu continu reimburs friction involv even higher degre
sale organ time/resourc devot sinuva vs management previous
thought address add tl hire result deceler growth
trend project growth re-acceler high
growth med-tech peer management intend re-alloc resourc toward sinuva howev
need achiev lower level sinuva revenue management
previous contempl moreov realloc continu come expens
propel base biz revenue growth leadership chang ceo thoma west effect
anoth sizabl revenue guidanc re-set could set stage improv execut howev
less inclin view new rang conserv given guidanc move
target time leadership transit alway carri risk lot
uncertainti mind when/if sinuva initi fact intend
impact also xent catalyst tilt toward j-code sinuva win
unlik meaning impact xent drug coat balloon initi could
promis still earli wont know data/regulatori pathway late
revenue potenti unlik get thumb
biggest nt risk mp rate takeout view alway consid
takeout candid could help protect stock downsid given lower sinuva
propel revenue growth trajectori see less upsid takeout
unchang see increas risk compani abil drive penetr result
reduc well estim
pt base updat dcf assum
discount rate long-term free cash flow growth rate start gener
posit free cash flow nopat a-capex-work capit rapidli increas
margin thereaft dcf horizon go-forward tax rate
risk-adjust sinuva forecast sale compound-annual-growth-rate
vs current trade ev/sal reflect discount comp
group high growth med-tech peer
trade average ev/sal think
discount warrant vs small-cap med-tech group average given flat y/i growth prospect
acceler potenti low-teen compani refocus effort
propel sinuva launch kick fuller gear compani acceler revenue growth
high-teen xent valuat gap vs high-multipl small-cap carve-out
grower could narrow even reach pariti even possibl premium eventu
stage limit confid near-term sinuva upsid potenti
risk adjust sinuva dcf attempt account reimbursement/execut risk
associ sinuva launch exercis consid two possibl upsid scenario
 reimburs friction eas faster anticip due higher multipl
takeout assum risk adjust out-year sinuva forecast dcf yield
closer appli closer-to-the-p group average multipl ev/
sale impli assum cash balanc end less
estim could risk exist product propel propel contour sale take
longer expect materi adopt compani product progress
level model reimburs reduct went effect jan
begin greater impact util privat insur follow lead
reduc payment level sinu procedur compani ultim receiv broader
reimburs addit favor coverag decis hinder greater adopt
secur reimburs sinuva product competitor abl pursue/
develop solut compet xent product renew initi new leadership
manag sinvua ramp propel util pan take longer expect
result tangibl growth acceler
rate zimmer hold nyse outperform pt view strong
turnaround stori make new leadership think compani improv
execut eventu drive faster ep growth compani come side
manufactur suppli recoveri post re-acceler top line given potenti
may even begin engag portfolio re-shap beyond
shift exposur toward faster-grow end-mkts/subseg end day
gener solid hold market-lead posit across key orthoped market
favor demograph tailwind trade signific price-to-earnings discount large-
cap med-tech think zbh steep discount vs peer narrow compani improv
execut eventu drive faster ep growth
trade fairli steep discount large-cap med-tech group price-to-earnings average
believ level discount vs large-cap peer warrant given average top-lin growth
execut risk relat zbh-biomet integr suppli issu think current
discount vs peer wide believ ultim busi time
capabl gener hsd ep growth gradual top-lin acceler low- mid-
singl digit growth territori pt assum trade
ep narrow valuat gap vs large-cap med-tech average
forward multipl would zbh current price-to-earnings multipl would still repres
discount large-cap exclud ew group average price-to-earnings
compani large-cap group includ alc
risk valuat includ abl execut post-biomet ldrh deal
synergi guidanc take longer address suppli issu build safeti
stock inventori -- -which could limit co abil meet demand and/or regain market share futur
qtr crucial sale growth acceler stori underli ortho recon growth
rate slow vs current expect level price eros industri ortho recon price
occur dramat pace expect wors steadi y/i declin
rang unabl off-set asp price declin posit mix benefit relat new
product offer could hinder long-term share price appreci
robot total knee categori begin acceler faster-than-expect and/or abl
capit rosa knee applic time fashion fda approv
million except per-shar data note fy end decemb
interest income/ expens
basic dilut share outstand mm
compani report svb leerink llc estim
dollar million except per-shar data
loss extinguish debt
chang fair valu cont consider
chang fair valu deriv liabil
dil share outstand incom
sale pro-forma
compani report svb leerink llc estim
dollar million except per share data
adj interest expens net
adjust income/ loss tax
compani report svb leerink llc estim
note restat revenu certain incom statement item annual quarterli annual compli adopt begin
dollar million except per share data
good sold
oper incom ex-item amort
pre-tax incom ex-item amort
dilut averag share million
sg adjust sale
sg adjust ex-amort sale
 total sale
oper expens adjust sale
oper expens adjust ex-amort sale
day adj sale organ growth rate ex- acq
compani report svb leerink llc estim
dollar million except per share data
sale
sell gener administr
research develop
amort intang asset
provis benefit incom tax
net income/ loss cont op
weighted-averag number share outstand dilut
compani report svb leerink llc estim full year estim continu oper ex-larg
dollar million except per share data
product sold ex-intang amort
research develop expens
sell gener administr expens
income/ loss attribut non-controlling
adj dilut averag share million
gross margin ex devic tax
oper expens sale
sg sale
 sale
compani data svb leerink llc estim
note restat certain incom statement item reflect adopt account standard updat revenu contract custom topic account standard updat
